Deal Watch: From The Sidelines Of J.P. Morgan, Lots Of Discovery Deals
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.
You may also be interested in...
Recorlev (levoketoconazole) demonstrates efficacy and liver safety in a Phase III single-arm study, but needs to live down the bad rap of ketoconazole and ultimately escape a black box warning.
Dong-A ST’s Head of Research Taeyoung Yoon talks to Scrip about the leading South Korean pharma’s ambitions to become a developer of original drugs, its innovative drug R&D strategy, and other major achievements as it reshapes its business.
Observers are weighing up whether it makes sense for Celgene to spend in the region of $12bn and plump for the promise of Juno's CAR-T program and whether it would be forced to abandon another promising partner in bluebird.